Simiso Sokhela

1.6k total citations · 2 hit papers
31 papers, 791 citations indexed

About

Simiso Sokhela is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Simiso Sokhela has authored 31 papers receiving a total of 791 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Infectious Diseases, 18 papers in Virology and 14 papers in Emergency Medicine. Recurrent topics in Simiso Sokhela's work include HIV/AIDS drug development and treatment (24 papers), HIV Research and Treatment (18 papers) and HIV/AIDS Research and Interventions (14 papers). Simiso Sokhela is often cited by papers focused on HIV/AIDS drug development and treatment (24 papers), HIV Research and Treatment (18 papers) and HIV/AIDS Research and Interventions (14 papers). Simiso Sokhela collaborates with scholars based in South Africa, United Kingdom and United States. Simiso Sokhela's co-authors include François Venter, Godspower Akpomiemie, Andrew Hill, Kaitlyn McCann, Ambar Qavi, Michelle Moorhouse, Celicia Serenata, Bryony Simmons, Nomathemba Chandiwana and Natasha Arulappan and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and SHILAP Revista de lepidopterología.

In The Last Decade

Simiso Sokhela

28 papers receiving 789 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

2019 442 citations François Venter, Michelle Moorhouse et al. New England Journal of Medicine profile →
Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial

2024 47 citations Cissy Kityo, Ivan Mambule et al. The Lancet Infectious Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Simiso Sokhela South Africa	12	606	484	326	132	59	31	791
Nomathemba Chandiwana South Africa	9	474 0.8×	372 0.8×	248 0.8×	105 0.8×	39 0.7×	26	628
Ambar Qavi United Kingdom	7	503 0.8×	368 0.8×	245 0.8×	104 0.8×	46 0.8×	9	670
Masebole Masenya South Africa	4	366 0.6×	303 0.6×	195 0.6×	78 0.6×	32 0.5×	4	481
Barbara Menzaghi Italy	16	316 0.5×	270 0.6×	180 0.6×	115 0.9×	74 1.3×	46	534
Nkuli Mashabane South Africa	5	356 0.6×	302 0.6×	200 0.6×	74 0.6×	33 0.6×	7	478
Sally Bebawy United States	12	457 0.8×	319 0.7×	240 0.7×	177 1.3×	27 0.5×	21	646
Amit C. Achhra Australia	13	330 0.5×	297 0.6×	226 0.7×	89 0.7×	35 0.6×	26	485
Giovanni Penco Italy	14	380 0.6×	210 0.4×	251 0.8×	101 0.8×	61 1.0×	35	493
Michael Aboud United Kingdom	13	950 1.6×	407 0.8×	703 2.2×	172 1.3×	40 0.7×	31	1.1k
Daniel Seekins United States	19	532 0.9×	161 0.3×	324 1.0×	211 1.6×	41 0.7×	30	746

Countries citing papers authored by Simiso Sokhela

Since Specialization

Citations

This map shows the geographic impact of Simiso Sokhela's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simiso Sokhela with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simiso Sokhela more than expected).

Fields of papers citing papers by Simiso Sokhela

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simiso Sokhela. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simiso Sokhela. The network helps show where Simiso Sokhela may publish in the future.

Co-authorship network of co-authors of Simiso Sokhela

This figure shows the co-authorship network connecting the top 25 collaborators of Simiso Sokhela. A scholar is included among the top collaborators of Simiso Sokhela based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simiso Sokhela. Simiso Sokhela is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kityo, Cissy, Ivan Mambule, Simiso Sokhela, et al.. (2025). Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial. Nature Medicine. 32(1). 168–177.

Rockstroh, Jürgen K., Roger Paredes, Pedro Cahn, et al.. (2025). Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial. Clinical Infectious Diseases. 81(2). 322–332.

Sokhela, Simiso, Jennifer Manne‐Goehler, Samanta Tresha Lalla‐Edward, et al.. (2025). REPRIEVE final results: What does it mean for guidelines in low‐ and middle‐income countries?. Journal of the International AIDS Society. 28(6). e26525–e26525.

Manne‐Goehler, Jennifer, June Fabian, Simiso Sokhela, et al.. (2024). Blood pressure increases are associated with weight gain and not antiretroviral regimen or kidney function: a secondary analysis from the ADVANCE trial in South Africa. Journal of the International AIDS Society. 27(7). e26268–e26268. 1 indexed citations

Wasmann, Roeland E., Godspower Akpomiemie, Nomathemba Chandiwana, et al.. (2024). Determinants of early change in serum creatinine after initiation of dolutegravir‐based antiretroviral therapy in South Africa. British Journal of Clinical Pharmacology. 90(5). 1247–1257. 1 indexed citations

Hill, Andrew, Simiso Sokhela, Bryony Simmons, et al.. (2024). Low CD4 counts predict excessive weight gains during first-line treatment for HIV. Journal of Antimicrobial Chemotherapy. 79(9). 2369–2378. 4 indexed citations

Brennan, Alana T., Beatrice Vetter, François Venter, et al.. (2024). The cost of adding rapid screening for diabetes, hypertension, and COVID-19 to COVID-19 vaccination queues in Johannesburg, South Africa. BMC Public Health. 24(1). 1900–1900. 1 indexed citations

Venter, François, et al.. (2024). Long-acting antiretroviral therapy in low-income and middle-income countries: considerations for roll-out. Current Opinion in HIV and AIDS. 20(1). 19–24. 1 indexed citations

Kityo, Cissy, Ivan Mambule, Simiso Sokhela, et al.. (2024). Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial. The Lancet Infectious Diseases. 24(10). 1083–1092. 47 indexed citations breakdown →

10.

Sokhela, Simiso, Godspower Akpomiemie, Nomathemba Chandiwana, et al.. (2024). DORA: 48‐week weight and metabolic changes in Black women with HIV, in a phase IIIb switch study from dolutegravir‐ or efavirenz‐ to doravirine‐based first‐line antiretroviral therapy. HIV Medicine. 26(1). 81–96. 1 indexed citations

11.

Wasmann, Roeland E., Phumla Sinxadi, Simiso Sokhela, et al.. (2023). Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population. CPT Pharmacometrics & Systems Pharmacology. 12(6). 821–830. 4 indexed citations

12.

Mpoudi-Etame, Mireille, Charles Kouanfack, Éric Delaporte, et al.. (2023). Risks of metabolic syndrome in the ADVANCE and NAMSAL trials. SHILAP Revista de lepidopterología. 5. 1133556–1133556. 11 indexed citations

13.

Maartens, Gary, Yuki Bradford, François Venter, et al.. (2022). Pharmacogenetics of Dolutegravir Plasma Exposure Among Southern Africans With Human Immunodeficiency Virus. The Journal of Infectious Diseases. 226(9). 1616–1625. 8 indexed citations

14.

Sokhela, Simiso, Andrew Hill, Bryony Simmons, et al.. (2022). Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection. Journal of Antimicrobial Chemotherapy. 77(10). 2706–2712. 6 indexed citations

15.

Griesel, Rulan, Phumla Sinxadi, John A. Joska, et al.. (2022). Pharmacokinetic and pharmacogenetic associations with dolutegravir neuropsychiatric adverse events in an African population. Journal of Antimicrobial Chemotherapy. 77(11). 3110–3117. 4 indexed citations

16.

Chandiwana, Nomathemba, Simiso Sokhela, Lubbe Wiesner, et al.. (2022). Effect of obesity on dolutegravir exposure in Black Southern African adults living with HIV. Southern African Journal of HIV Medicine. 23(1). 1452–1452. 3 indexed citations

17.

Griesel, Rulan, Roeland E. Wasmann, Simiso Sokhela, et al.. (2021). Concentration–response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy. British Journal of Clinical Pharmacology. 88(3). 883–893. 13 indexed citations

18.

Venter, François, Michelle Moorhouse, Simiso Sokhela, et al.. (2019). Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. New England Journal of Medicine. 381(9). 803–815. 442 indexed citations breakdown →

19.

Venter, François, Michelle Moorhouse, Simiso Sokhela, et al.. (2019). Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial. The Lancet HIV. 6(7). e428–e437. 12 indexed citations

20.

Pepper, Dominique J., Suzaan Marais, Robert J. Wilkinson, et al.. (2010). Clinical deterioration during antituberculosis treatment in Africa: Incidence, causes and risk factors. BMC Infectious Diseases. 10(1). 83–83. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact